Clinical Trial Update: Samsca PMS in ADPKD Patients

View source ↗

Summary

A completed post-marketing safety surveillance study of Samsca (tolvaptan) in patients with autosomal dominant polycystic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Safety | Status: COMPLETED